ClinicalTrials.gg

Program

nilvanstomig

Also written as “ZG005 for Injection”, “ZG005” and “ZG005 Powder for Injection”.

Its studies are mostly in Carcinoma, Neuroendocrine · Carcinoma, Hepatocellular · Uterine Cervical Neoplasms · Carcinoma, Non-Small-Cell Lung · Lymphoma, led by Suzhou Zelgen Biopharmaceuticals.

Furthest: phase 3, since Sep 4, 202615 company-led studies, 13 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou Zelgen Biopharmaceuticals1513 open or runningphase 3since Sep 4, 2026Jan 22, 2024Apr 2027phase 2 · NCT06903377

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 22, 2024First studies: 3 phase 2 studiesFirst studyNCT06233292, NCT06239298, NCT06241235
  2. Apr 15, 2024Phase 2 study in Carcinoma, NeuroendocrineNCT06372626 · 93 planned · China
  3. Aug 14, 2024Phase 2 study in Carcinoma, HepatocellularNCT06558227 · 90 planned · China
  4. Mar 13, 20252 phase 2 studiesNCT06883526, NCT06903377
  5. Apr 7, 20252 phase 2 studies in Advanced Solid TumorNCT06938880, NCT06927687
  6. Jun 18, 2025Phase 2 study in Small Cell Lung CarcinomaNCT07038096 · 350 planned · China
  7. Jul 14, 20252 phase 2 studiesNCT07080216, NCT07099547
  8. Aug 19, 2025Phase 2 study in Advanced Solid TumorNCT07142837 · 153 planned · China
  9. Sep 4, 20262 phase 3 studiesPhase 3 reachedNCT07813572, NCT07833839

Ahead

  1. Apr 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06903377
  2. Apr 2027Primary completion: phase 2 study in LymphomaNCT06883526
  3. May 2027Primary completion: phase 2 study in Advanced Solid TumorNCT06938880
  4. May 2027Primary completion: phase 2 study in Advanced Solid TumorNCT06927687

TargetBeta

PDCD1 →TIGIT →read by rule
“A humanized bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhi”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
rilvegostomigAstraZenecaphase 324

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07833839Carcinoma, Neuroendocrine · China3Not yet recruitingOct 2031440
NCT07813572Carcinoma, Hepatocellular · China3RecruitingSep 2031600
NCT07142837Advanced Solid Tumor · China2Not yet recruitingOct 2027153
NCT07099547Biliary Tract Carcinoma · China2RecruitingDec 202760
NCT07080216Uterine Cervical Neoplasms · China2RecruitingAug 2027120
NCT07038096Small Cell Lung Carcinoma · China2RecruitingSep 2027350
NCT06938880Advanced Solid Tumor · China2RecruitingMay 202760
NCT06927687Advanced Solid Tumor · China2Active, not recruitingMay 202750
NCT06903377Carcinoma, Non-Small-Cell Lung · China2RecruitingApr 202750
NCT06883526Lymphoma · China2RecruitingApr 202760
NCT06558227Carcinoma, Hepatocellular · China2RecruitingSep 202690
NCT06372626Carcinoma, Neuroendocrine · China2RecruitingJul 202693
NCT06241235Uterine Cervical Neoplasms · China2RecruitingMay 202648
NCT06239298Solid Tumor · China2UNKNOWNMar 2026130
NCT06233292Solid Tumors · China2CompletedJul 22, 2026125

How it is read

Names in the registry

  • “ZG005 for Injection”, 7 entries
  • “ZG005”, 5 entries
  • “ZG005 Powder for Injection”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.